Jitters over prospects with any candidate in Alzheimer's disease (AD) failed to deter investors from putting up to $30.8 million into Transition Therapeutics Inc., which not only has AD work ongoing but also a phase II trial in type 2 diabetes with heavyweight partner Eli Lilly and Co.